siRNA rescues nonhuman primates from advanced Marburg and Ravn virus disease
Open Access
- 23 October 2017
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 127 (12) , 4437-4448
Abstract
Ebolaviruses and marburgviruses belong to the family Filoviridae and cause high lethality in infected patients. There are currently no licensed filovirus vaccines or antiviral therapies. The development of broad-spectrum therapies against members of the Marburgvirus genus, including Marburg virus (MARV) and Ravn virus (RAVV), is difficult because of substantial sequence variability. RNAi therapeutics offer a potential solution, as identification of conserved target nucleotide sequences may confer activity across marburgvirus variants. Here, we assessed the therapeutic efficacy of lipid nanoparticle (LNP) delivery of a single nucleoprotein–targeting (NP-targeting) siRNA in nonhuman primates at advanced stages of MARV or RAVV disease to mimic cases in which patients begin treatment for fulminant disease. Sixteen rhesus monkeys were lethally infected with MARV or RAVV and treated with NP siRNA-LNP, with MARV-infected animals beginning treatment four or five days after infection and RAVV-infected animals starting treatment three or six days after infection. While all untreated animals succumbed to disease, NP siRNA-LNP treatment conferred 100% survival of RAVV-infected macaques, even when treatment began just 1 day prior to the death of the control animals. In MARV-infected animals, day-4 treatment initiation resulted in 100% survival, and day-5 treatment resulted in 50% survival. These results identify a single siRNA therapeutic that provides broad-spectrum protection against both MARV and RAVV.Keywords
Funding Information
- NIAID/NIH (U19AI109711)
This publication has 31 references indexed in Scilit:
- Rescue of non-human primates from advanced Sudan ebolavirus infection with lipid encapsulated siRNANature Microbiology, 2016
- Comparison of the Pathogenesis of the Angola and Ravn Strains of Marburg Virus in the Outbred Guinea Pig ModelThe Journal of Infectious Diseases, 2015
- Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primatesNature, 2015
- Ebola haemorrhagic fever in west AfricaThe Lancet Infectious Diseases, 2014
- Advanced antisense therapies for postexposure protection against lethal filovirus infectionsNature Medicine, 2010
- Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept studyThe Lancet, 2010
- Marburg Virus Angola Infection of Rhesus Macaques: Pathogenesis and Treatment with Recombinant Nematode Anticoagulant Protein c2The Journal of Infectious Diseases, 2007
- Marburg Hemorrhagic Fever Associated with Multiple Genetic Lineages of VirusNew England Journal of Medicine, 2006
- A systematic analysis of the silencing effects of an active siRNA at all single-nucleotide mismatched target sitesNucleic Acids Research, 2005
- Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cellsNature, 2001